Premium
Moclobemide versus amitriptyline in the treatment of depression: two small double‐blind multicentre studies in Belgium
Author(s) -
Beckers G.,
Vereecken A.,
Bleeker E.,
Jaunes C.,
Sieben G.,
Faidherbe J.,
Wolfram C.,
Berger M.,
Hellstern K.,
Ward J.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05329.x
Subject(s) - moclobemide , amitriptyline , medicine , depression (economics) , antidepressant , anesthesia , macroeconomics , hippocampus , economics
Moclobemide was compared with amitriptyline for antidepressent efficacy, safety and tolerance. Two studies were conducted, both over at least 4 weeks; in the first, 8 patients were given moclobemide in doses ranging from 300 to 328 mg, and 9 patients amitriptyline in doses of 75 to 96 mg; in the second, the numbers were 13 on moclobemide and 14 on amitriptyline, and the mean doses were 294‐408 mg and 95‐129 mg respectively. Both studies showed the 2 treatments to be equally effective, and there were no significant differences at any point. Moclobemide appeared slightly more effective and slightly better tolerated than amitriptyline, but the numbers were too small for any valid conclusion.